Preview Mode Links will not work in preview mode

Mar 26, 2020

A special video supplement to a CME conference held during the 61st ASH Annual Meeting featuring expert comments on the management of acute myeloid leukemia. Featuring perspectives from Dr Daniel A Pollyea.

  • Choice of first-line therapy for acute myeloid leukemia (AML); selection of patients who are fit for intensive chemotherapy (00:00)
  • Perspective on the choice of hypomethylating agent (HMA) to combine with venetoclax (04:03)
  • Clinical implications of the Phase III QUAZAR AML-001 study assessing maintenance CC-486 for patients with AML in first remission (06:46)
  • Potential implications of combining CC-486 with venetoclax for AML (10:25)
  • Biologic rationale for the synergistic effect of venetoclax with an HMA or low-dose cytarabine for patients with AML (13:24)
  • Identifying nonresponders to venetoclax-based combination therapy; managing the monocytic (FABM5) subgroup of AML (17:00)
  • Rationale for combining venetoclax with azacitidine; optimal duration of HMA therapy (20:13)
  • Monitoring bone marrow counts in patients with AML receiving venetoclax-based therapy; role of dose interruptions in managing cytopenias (23:32)
  • Effect of venetoclax-based combinations on extramedullary disease (27:36)
  • Strategies to mitigate tumor lysis syndrome associated with venetoclax-based therapy (28:38)
  • Perspective on the use of prophylaxis to reduce the risk of infections associated with venetoclax (30:26)
  • Recommendations for hospitalization of patients with AML receiving venetoclax-based therapies (33:07)
  • Use of venetoclax/HMA therapy in patients with AML and high white blood cell counts (35:41)
  • Benefit with the addition of venetoclax to an HMA for patients with AML (37:35)
  • Outcomes for patients with AML experiencing disease relapse on venetoclax with an HMA; mechanisms of resistance to the venetoclax and HMA combination (39:29)
  • Potential for venetoclax-based combinations for patients with AML eligible for intensive induction chemotherapy (43:41)
  • Case: A woman in her mid-30s with high-risk AML who is ineligible for induction chemotherapy achieves a complete response with venetoclax and azacitidine (48:06)
  • Perspective on the potential use of venetoclax/HMA prior to transplant (50:32)
  • Therapeutic approach for older patients with AML harboring FLT3 and IDH mutations (53:26)
  • Challenges associated with the use of venetoclax-based combinations (56:12)
  • Quality-of-life impact and tolerability of venetoclax/HMA therapy (59:16)
  • Emerging options for patients with AML harboring p53 mutations (1:01:03)
  • Rationale for the investigation of the novel, first-in-class small molecule APR-246 in combination with azacitidine for patients with AML with TP53 mutations (1:03:30)
  • Activity and tolerability of APR-246 in AML (1:05:53)

CME information and select publications